Literature DB >> 9192690

7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide: a partial modulator of AMPA receptor desensitization devoid of neurotoxicity.

F Impagnatiello1, A Oberto, P Longone, E Costa, A Guidotti.   

Abstract

In cerebellar granule neurons of neonatal rats micromolar concentrations of 7-chloro-3-methyl-3,4-dihydro-2H-1,2, 4-benzothiadiazine S,S-dioxide (IDRA-21) and cyclothiazide, two negative modulators of the spontaneous agonist-dependent rapid desensitization of alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA)-gated ion channels, facilitate AMPA receptor function by increasing the content of free cytosolic Ca2+ as measured by single-cell fura-2 acetoxymethyl ester (Fura-2) Ca2+-dependent fluorescence and intracellular Na+ measured with the sodium-binding bezofuran isophthalate acetoxymethyl ester fluorescence indicator. IDRA-21 increases intracellular Na+ transient with a threshold (5 microM) that is approximately 10 times higher and has an intrinsic activity significantly lower than that of cyclothiazide. By virtue of its low intrinsic activity, IDRA-21 elicits a free cytosolic Ca2+ transient increase that is shorter lasting than that elicited by cyclothiazide even when the drug is left in contact with cultured granule cells for several minutes. Additionally, while dose dependently, 5-25 microM cyclothiazide in the presence of AMPA is highly neurotoxic, IDRA-21 (up to 100 microM) is devoid of neurotoxicity. The neurotoxicity elicited by cyclothiazide persists in the presence of dizocilpine (an antagonist of N-methyl-D-aspartate-selective glutamate receptors) but is blocked by 2,3-dihydroxy-6-nitrosulfamoylbenzo[f]quinoxaline (a competitive AMPA receptor antagonist) and the 1-(aminophenyl)-4-methyl-7, 8-methylendioxy-5H-2,3-benzodiazepine (GYKI 52466; a noncompetitive AMPA receptor antagonist). Since the doses of IDRA-21 that enhance cognitive processes in rats and monkeys are several orders of magnitude lower than those required to elicit marginal neurotoxicity in cultured neurons, it can be surmised that IDRA-21 is a potent cognition-enhancing drug virtually devoid of neurotoxic liability because it acts as a partial negative allosteric modulator of AMPA receptor desensitization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192690      PMCID: PMC21283          DOI: 10.1073/pnas.94.13.7053

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Gangliosides normalize distorted single-cell intracellular free Ca2+ dynamics after toxic doses of glutamate in cerebellar granule cells.

Authors:  G A de Erausquin; H Manev; A Guidotti; E Costa; G Brooker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.

Authors:  S D Donevan; M A Rogawski
Journal:  Neuron       Date:  1993-01       Impact factor: 17.173

3.  AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate.

Authors:  K M Partin; M W Fleck; M L Mayer
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

4.  Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex.

Authors:  M Favaron; H Manev; H Alho; M Bertolino; B Ferret; A Guidotti; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 5.  Excitatory amino acid receptors in the vertebrate central nervous system.

Authors:  G L Collingridge; R A Lester
Journal:  Pharmacol Rev       Date:  1989-06       Impact factor: 25.468

Review 6.  New developments in Ca2+ channel antagonists.

Authors:  R A Janis; D J Triggle
Journal:  J Med Chem       Date:  1983-06       Impact factor: 7.446

7.  Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus.

Authors:  A Arai; M Kessler; G Rogers; G Lynch
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

8.  Fluorescence ratio imaging of cytosolic free Na+ in individual fibroblasts and lymphocytes.

Authors:  A T Harootunian; J P Kao; B K Eckert; R Y Tsien
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

9.  2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.

Authors:  M J Sheardown; E O Nielsen; A J Hansen; P Jacobsen; T Honoré
Journal:  Science       Date:  1990-02-02       Impact factor: 47.728

10.  Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam.

Authors:  I Ito; S Tanabe; A Kohda; H Sugiyama
Journal:  J Physiol       Date:  1990-05       Impact factor: 5.182

View more
  5 in total

Review 1.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 2.  A neurochemical basis for an epigenetic vision of psychiatric disorders (1994-2009).

Authors:  Alessandro Guidotti; Dennis R Grayson
Journal:  Pharmacol Res       Date:  2011-06-15       Impact factor: 7.658

3.  Glutamate receptor desensitization block potentiates the stimulated GABA release through external Ca2+-independent mechanisms from granule cells of olfactory bulb.

Authors:  E H Jaffe; L Figueroa
Journal:  Neurochem Res       Date:  2001-11       Impact factor: 3.996

4.  Changes in AMPA receptor-spliced variant expression and shift in AMPA receptor spontaneous desensitization pharmacology during cerebellar granule cell maturation in vitro.

Authors:  P Longone; F Impagnatiello; J M Mienville; E Costa; A Guidotti
Journal:  J Mol Neurosci       Date:  1998-08       Impact factor: 3.444

5.  A novel class of allosteric modulators of AMPA/Kainate receptors.

Authors:  Giuseppe Cannazza; Krzysztof Jozwiak; Carlo Parenti; Daniela Braghiroli; Marina M Carrozzo; Giulia Puia; Gabriele Losi; Mario Baraldi; Wolfgang Lindner; Irving W Wainer
Journal:  Bioorg Med Chem Lett       Date:  2008-12-30       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.